CN101698885A - Liquid-phase chip for detecting expression level of mRNAs of genes related to therapeutic effect of anti-metabolism chemotherapeutic medicament - Google Patents

Abstract

The invention discloses a liquid-phase chip for detecting the expression level of the mRNAs of genes related to the therapeutic effect of an anti-metabolism chemotherapeutic medicament, which mainly comprises: microspheres coupled with support probes modified by aminos, support extension probes connecting the support probes and the mRNAs of the target genes and amplification extension probes connecting the mRNAs of the target genes and a signal detection component, wherein each support extension probe comprises a specific sequence of which the 5'-terminal can be combined with the corresponding mRNA of the target gene, a spacer arm sequence and a sequence of which the 3'-terminal is complementary to and can be matched with the specific sequence of the support probe; and each amplification extension probe comprises a specific sequence of which the 5'-terminal can be combined with the mRNA of the target gene, a spacer arm sequence and a sequence of which the 3'-terminal is complementary to and can be matched with a mark probe. The method also discloses a method for detecting the expression level of the mRNAs of the genes related to the therapeutic effect of the anti-metabolism chemotherapeutic medicament by using the liquid-phase chip. The method has the advantages that: on one hand as steps such as RNA extraction, reverse transcription and PCR are avoided in a detection process, the detection result suffers little influences of the quality of the RNA in a sample, and the accuracy of the detection result is guaranteed; on the other hand, liquid-phase chip technology realizes multi-index parallel detection, so a plurality of reference genes can be set in one time of detection and the detection result is more reliable.

Description

Anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex and detection method

Technical field

The invention belongs to biology field, relate to medical science and biotechnology, the concrete relevant mrna expression of anti-metabolism chemotherapeutical medicine curative effect that relates to detects liquid-phase chip and detection method.

Background technology

The chemotherapeutics treatment is one of main means for the treatment of at present tumour, can be divided into alkylating agent class, anti-metabolism, anti-microtubule class, topoisomerase enzyme inhibitor, antibiotics, hormones, molecular target class etc.Wherein, antimetabolite commonly used has folic acid antagonists, purine analogue, pyrimidine analogue etc., the structure of this class medicine and the metabolic similar of human body normal physiological, thereby can disturb the function of eubolism thing are blocked at nucleic acid synthetic different levels and are produced curative effect.Owing to do not find the specificity difference on normal cell and the tumour cell Proteometabolism as yet, the mechanism of onset has been to utilize that base and enzyme are the difference of content in normal cell and the tumour cell, thereby the disadvantage of antimetabolite is when suppressing tumour cell the vigorous normal cell of hyperplasia also to be had suitable toxicity, and resistance easily takes place.Discover that in a large number (TYMS, TS) waiting the expression level of target gene is the important evidence that can the prediction patient use antimetabolitas and curative effect thereof for ribose nucleotide reducing ferment M 1 (RRM1), thymine synthetase.

(1) gemcitabine and ribose nucleotide reducing ferment M 1 (RRM1)

Gemcitabine is the cell cycle specific antimetabolitas, mainly acts on the DNA tumour cell of synthesis phase, i.e. S phase cell.RRM1 is the rate-limiting enzyme in the DNA route of synthesis, and participates in the pathways metabolism of gemcitabine.Find RRM1 high expression level among the gemcitabine resistance patient by microarray analysis, and confirm that the RRM1 expression level is also influential to the platinum medicine treatment simultaneously among the gemcitabine resistance patient.The mRNA expression level that studies show that RRM1 and ERCC1 has very strong forward dependency.The patients with lung cancer of low RRM1 mRNA level is relative with cis-platinum susceptibility higher to gemcitabine, and median survival interval prolongs, and high RRM1 expresses patient's efficacy and median survival interval obviously descends.

(2) pyrimidines antimetabolic chemotherapeutical medicine (5-FU) and thymine synthetase (TYMS, TS)

(such medicine also has Tegafur, carmofur, floxuridine, doxifluridine and capecitabine etc. to 5-FU for Fluracil, the fluorouracil) fluorouracil in the genus antimetabolitas.These medicines all are converted into 5-FU in vivo, bring into play antitumor action then.5-FU is one of medicine that uses the earliest, and is still indispensable broad-spectrum anti-tumor medicine in the cancer therapy so far.Though the antitumor curative effect of fluorouracil drug extensively approved, the individual difference of drug effect is very big and in various degree toxic side effect arranged after patient's medication.It is bigger to marrow and gastrointestinal toxicity, often causes alopecia, neurotoxicity and cutaneous pigmentation, accidental liver, renal impairment.

5-FU is the derivative that the hydrogen on 5 of the uridylics is replaced by fluorine, in cell, change 5 FU 5 fluorouracil deoxynucleotide (5F-dUMP) into, and suppress the deoxythymidine acid enzyme, stop deoxyuridylic acid (dUMP) to methylate and change deoxythymidylic acid (dTMP) into, thereby influence the synthetic of DNA.In addition, 5-FU can be converted into the 5 FU 5 fluorouracil nucleosides in vivo, mixes the synthetic of interferencing protein among the RNA with pseudo-metabolite form, so to being in each cell cycle cell effect is arranged also.

TYMS is a pyrimidine nucleotide synthetic rate-limiting enzyme, also is the target enzyme of 5-FU performance cytotoxicity.The meta-bolites 5F-dUMP of 5-FU and TYMS, 5, the combination of 10-methylene tetrahydrofolate forms stable ternary complex, hinders the physiological process that TYMS catalysis dUMP changes dTMP into, thereby suppresses dna replication dna and reparation.There are individual difference in the expression level of TYMS gene mRNA, stability and translation efficiency, and can cause tumour patient to the chemotherapeutic efficacy difference of 5-FU for the basis.A large amount of clinical studies show, the patient of TYMSmRNA high expression level produces resistance to 5-FU, and promptly the patient that the TYMS gene expression dose is low is to 5-FU class medicaments insensitive, on the contrary the high patient of expression level shows resistance.Show in the clinical study to colorectal cancer patients, the mRNA expression level of TYMS relevant with the curative effect of 5-FU/ oxaliplatin treatment (p＜0.001), the low patient who expresses of TYMS mRNA is after the treatment beginning, and its survival probability is apparently higher than the high expression level person.Therefore, the expression level of TYMS may be the key index of prediction 5-FU curative effect.

(3) housekeeping gene B2M (B2M), TfR (TFRC) and TATA frame conjugated protein (TBP)

But housekeeping gene is stably express in vivo generally, but because this stably express is relative, under certain pathological state or medicining condition, the expression of the housekeeping gene that some is commonly used also can change.The gene that is chosen in stably express in our institute's research object is made housekeeping gene, and is most important to the accuracy that guarantees detected result.Therefore, the present invention screens from the housekeeping gene commonly used of some amount, determines 3 suitable housekeeping genes, is respectively: B2M (B2M), TfR (TFRC), TATA frame conjugated protein (TBP).

Dependency based on above expression of gene level and chemotherapeutical medicine curative effect, the expert recommends the patient before accepting chemotherapeutics, the detection of the mrna expression that should be correlated with, help the clinician to formulate the personalized medicine scheme according to patient's individual difference, to improve curative effect of medication, reduce the generation of poisonous side effect of medicine.

At present, the technology that the mRNA expression level of gene is detected mainly contains: reverse transcription quantitative PCR method, real-time fluorescence quantitative PCR method, RNA in-situ nucleic acid hybridization (RISH) etc.Wherein, RISH is mainly used in the analysis tissue or intracellular rna distributes with the expression of understanding specific gene, and its process is long, complex operation, is not suitable for clinical application; And reverse transcription quantitative PCR method and real-time fluorescence quantitative PCR method, at first, these two kinds of methods all need to carry out RNA extracting, reverse transcription, and it is big that the result of detection is influenced by the RNA degraded; Secondly, these two kinds of methods are only carried out pcr amplification by a pair of primer, are easy to generate non-specific binding, thereby cause the false positive height; Once more, these two kinds of methods generally have only a housekeeping gene to compare, and its accuracy is subjected to the influence of pathological state easily; Therefore, reverse transcription quantitative PCR method and real-time fluorescence quantitative PCR method all exist the technological deficiency that is difficult to overcome as clinical application.

Liquid-phase chip technology is utilized the carrier of polystyrene microsphere as reaction, in the manufacturing processed of microballoon, mixes the staining agent of different ratios, thereby forms the microballoon of 100 kinds of different colours codings.Thereby different microballoon covalent attachment realize the nearly detection of running simultaneously of material to be checked in 100 at the probe molecule of difference thing to be detected.Therefore, we adopt liquid-phase chip technology can detect the mRNA expression level of a plurality of genes simultaneously, have realized the high-throughput that detects, and have improved detection efficiency greatly.

Summary of the invention

One of purpose of the present invention provides the mrna expression Liquid Detection chip relevant with the anti-metabolism chemotherapeutical medicine curative effect, and this liquid-phase chip can be used for detecting the expression level of following 5 kinds of target genes: RRM1, TYMS, B2M, TFRC, TBP.

The technical scheme that realizes above-mentioned purpose is as follows:

A kind of anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex mainly comprises:

(1) the support probe link coupled microballoon of modifying with amido, every support probe mainly comprise the spacerarm sequence of 5 ' end and 3 ' end with the specific sequence P1 that supports the extension probes complementary pairing, described support probe is selected from SEQ.NO.1-SEQ.NO.5, each target gene is selected a kind of microballoon for use, and every kind of microballoon has different fluorescence-encoded;

(2) connect the support extension probes of supporting probe and target gene mRNA, every support extension probes mainly comprise 5 ' end can with corresponding target gene mRNA bonded specific sequence P2, spacerarm sequence, 3 ' end can with the P3 sequence of the specific sequence P1 complementary pairing of corresponding support probe, the specific sequence P2 of described support extension probes includes: at the RRM1 gene be selected among the SEQ.NO.6-SEQ.NO.10 more than 2 or 2 and/or at the TYMS gene be selected among the SEQ.NO.11-SEQ.NO.15 more than 2 or 2; And at the B2M gene be selected among the SEQ.NO.16-SEQ.NO.20 more than 2 or 2, at the TFRC gene be selected among the SEQ.NO.21-SEQ.NO.25 more than 2 or 2 and at the TBP gene be selected among the SEQ.NO.26-SEQ.NO.30 more than 2 or 2;

(3) amplification extension probes, every amplification extension probes include 5 ' end can with target gene mRNA bonded specific sequence P4, spacerarm sequence, 3 ' terminal sequence P5,3 ' end also is modified with vitamin H; The specific sequence P4 of described amplification extension probes includes: at the RRM1 gene be selected among the SEQ.NO.31-SEQ.NO.40 more than 5 or 5 and/or at the TYMS gene be selected among the SEQ.NO.41-SEQ.NO.50 more than 5 or 5; And at the B2M gene be selected among the SEQ.NO.51-SEQ.NO.60 more than 5 or 5, at the TFRC gene be selected among the SEQ.NO.61-SEQ.NO.70 more than 5 or 5 and at the TBP gene be selected among the SEQ.NO.71-SEQ.NO.80 more than 5 or 5; Described P5 is for existing hairpin structure, do not form dimer between probe interior and probe, do not have mispairing, and P1, P2, P3, P4 and total mRNA between all do not have the sequence of non-specific binding.

Perhaps include:

(1) the support probe link coupled microballoon of modifying with amido, every support probe mainly comprise the spacerarm sequence of 5 ' end and 3 ' end can with the specific sequence P1 that supports the extension probes complementary pairing, described support probe is selected from SEQ.NO.1-SEQ.NO.5, each target gene is selected a kind of microballoon for use, and every kind of microballoon has different fluorescence-encoded;

(2) connect the support extension probes of supporting probe and target gene mRNA, every support extension probes mainly comprise 5 ' end can with corresponding target gene mRNA bonded specific sequence P2, spacerarm sequence, 3 ' end can with the P3 sequence of the specific sequence P1 complementary pairing of corresponding support probe, the specific sequence P2 of described support extension probes includes: at the RRM1 gene be selected among the SEQ.NO.6-SEQ.NO.10 more than 2 or 2 and/or at the TYMS gene be selected among the SEQ.NO.11-SEQ.NO.15 more than 2 or 2; And at the B2M gene be selected among the SEQ.NO.16-SEQ.NO.20 more than 2 or 2, at the TFRC gene be selected among the SEQ.NO.21-SEQ.NO.25 more than 2 or 2 and at the TBP gene be selected among the SEQ.NO.26-SEQ.NO.30 more than 2 or 2;

(3) amplification extension probes, every the amplification extension probes include 5 ' end can with target gene mRNA bonded specific sequence P4, spacerarm sequence, 3 ' terminal sequence P5; The specific sequence P4 of described amplification extension probes includes: at the RRM1 gene be selected among the SEQ.NO.31-SEQ.NO.40 more than 5 or 5 and/or at the TYMS gene be selected among the SEQ.NO.41-SEQ.NO.50 more than 5 or 5; And at the B2M gene be selected among the SEQ.NO.51-SEQ.NO.60 more than 5 or 5, at the TFRC gene be selected among the SEQ.NO.61-SEQ.NO.70 more than 5 or 5 and at the TBP gene be selected among the SEQ.NO.71-SEQ.NO.80 more than 5 or 5; Described P5 is for existing hairpin structure, do not form dimer between probe interior and probe, do not have mispairing, and P1, P2, P3, P4 and total mRNA between all do not have the sequence of non-specific binding; With

(4) label probe, described label probe have the sequence with amplification extension probes P5 complementary pairing, and end has biotin modification.

Preferably, described anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex, also include padding sequence, include: at the RRM1 gene be selected from one or more among the SEQ.NO.81-SEQ.NO.86, at the TYMS gene be selected from one or more among the SEQ.NO.87-SEQ.NO.90, at one or more among the SEQ.NO.91-SEQ.NO.98 that be selected from of B2M gene, and/or at one or more among the SEQ.NO.99-SEQ.NO.102 that be selected from of TFRC gene.

Preferably, described spacerarm sequence is 5-10 T; Described P5 consists of CCTATGCCTCCCGTGTCTA.

Another purpose of the present invention provides a kind of anti-metabolism chemotherapeutical medicine curative effect mRNA expression of gene associated level detection method.

Concrete technical scheme is as follows:

A kind of method that detects anti-metabolism chemotherapeutical medicine curative effect mRNA expression of gene associated level is used above-mentioned liquid-phase chip, mainly may further comprise the steps:

(1) lysed sample discharges total RNA, gets the cracking mixed solution;

(2) cracking mixed solution, coupling there are microballoon, support extension probes, the amplification extension probes of supporting probe are sealed in the hybridization plate, 54 ℃ ± 1 ℃, 600rpm shakes overnight incubation, support the sequence P3 of extension probes to combine with the P1 that supports probe is complementary, support the specific sequence P2 and the target mRNA specific combination of extension probes, thereby target mRNA is attached on the microballoon; The amplification extension probes has biotin labeling, amplifies thereby the P4 of amplification extension probes and target mRNA specific combination realize the cascade of target mRNA signal;

(3) product and the Streptavidin-phycoerythrin of step (two) react;

(4) detect by fluorescence detector.

Perhaps, mainly may further comprise the steps:

(1) lysed sample discharges total RNA, gets the cracking mixed solution;

(2) cracking mixed solution, coupling there are microballoon, support extension probes, the amplification extension probes of supporting probe are sealed in the hybridization plate, 54 ℃ ± 1 ℃, 600rpm shakes overnight incubation, support the sequence P3 of extension probes to combine complementary combination with the P1 that supports probe, support the specific sequence P2 and the target mRNA specific combination of extension probes, thereby target mRNA is attached on the microballoon; The P4 and the target mRNA specific combination of amplification extension probes;

(3) add label probe again, label probe has biotin labeling, and 50 ℃ ± 1 ℃, the 600rpm concussion was hatched 1 hour, and label probe combines with the sequence P5 complementary pairing of amplification extension probes, thereby the cascade that realizes target mRNA signal is amplified;

(4) product of step (three) and Streptavidin-algae red eggs are from reacting;

(5) detect by fluorescence detector.

Major advantage of the present invention is:

(1) the designed various probes of the present invention can carry out hybridization under the reaction conditions of homogeneous, and do not have non-specific binding between the various probe substantially; Designed probe specificity in detection is good, signal to noise ratio is high.Simultaneously, being used in combination of multiple probe makes liquid-phase chip and detection method form an intact system of detection effect.Use liquid-phase chip of the present invention and detection method, antimetabolic based chemotherapy medicament curative effect related gene mRNA expression level is detected, need not steps such as RNA extraction, reverse transcription, PCR, detected result is subjected in the sample quality influence of RNA less, has guaranteed the accuracy of detected result; On the other hand, compare (N 〉=3) with a plurality of housekeeping genes, detected result is not subject to the influence of pathological state, and the accuracy height makes detected result more reliable.

(2) the present invention uses is that the multidigit of probe is put the amplification that mode that special pairing, cascade amplify realizes signal, rather than the method for pcr amplification, improve detection signal, realized the specificity that detects, avoided the false positive of reverse transcription PCR and real-time fluorescence quantitative PCR technology.

(3) liquid-phase chip of the present invention and detection method are applicable to that flesh tissue, paraffin embedding fixing organization, tissue slice, puncture organize the equal samples type, to mRNA detection method, the characteristics that operation is simple and easy, accuracy is high, specificity is high are arranged compared with other.

Embodiment

Known to the those skilled in the art, described spacerarm sequence is spaced apart for being used for support probe and microsphere surface, supporting extension probes and amplification extension probes inside also to have the spacerarm sequence, by between probe sequence and amido, probe interior is provided with the spacerarm sequence of suitable length, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm (the preferred 2-4 of spacerarm length).Spacerarm of the present invention is preferably 5-10 T, in China, and the synthetic technology comparative maturity of T, cost is relatively low.

Embodiment 1 anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex test kit mainly includes:

One, coupling has the microballoon of support probe (SP)

Support probe to form by three parts, 5 ' end is and microballoon bonded amido end, 3 ' end is and supports extension probes bonded distinguished sequence P1, length is 16nt, the centre is the spacerarm sequence of 8 oligonucleotide T, each target gene is selected a kind of microballoon for use, and selects a support probe for use, and every kind of microballoon has different fluorescence-encoded.The support probe of each target gene is as shown in table 1:

The target gene that table 1 is different and select for use microballoon numbering, support probe (SP)

Gene	Microballoon number	SP sequence (5 ' → 3 ') NH 2+poly(dT)+P1	??SEQ?ID
				??RRM1	??43	??5’NH 2-TTTTTTTT-ACTATACTTCTTCACT	??1
??TYMS	??44	??5’NH 2-TTTTTTTT-TCATTCATTCATCAAT	??2
				??B2M	??22	??5’NH 2-TTTTTTTT-CTTTCTTTAATCTCAA	??3
??TFRC	??61	??5’NH 2-TTTTTTTT-CATTCAAATCTCAACT	??4
				??TBP	??33	??5’NH 2-TTTTTTTT-CAATTACTTCAAATCT	??5

All probes are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Synthetic is supported probe sterilization ddH ₂O is made into the stock solution of 100nmol/ml.The process of microballoon bag quilt is as follows:

Get 5 * 10 respectively ⁶The carboxylated microballoon of individual above-mentioned numbering (available from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds 10ul synthetic capture probe (100nmol/ml).EDC (N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide) (available from the Pierce Chemical company) working fluid of preparation 10ng/ml.Add the EDC working fluid of 2.5ul in the microballoon suspension, constant temperature was hatched 30 minutes, added the EDC working fluid of 2.5ul again, and constant temperature was hatched 30 minutes again.After reaction finished, the Tween-20 washing with 0.02% was once washed once with 0.1% SDS liquid again.Support the microballoon of probe to be resuspended in the Tris-EDTA solution [10mmol/L Tris (pH8.0), 1mmol/L EDTA] of 100ul being coated with after the washing, 2-8 ℃ keeps in Dark Place.

Two) support that with support extension probes (SE), the amplification extension probes (AE1) of target gene mRNA specific combination extension probes (SE) is to be connected the sequence of supporting between probe (SP) and the target gene mRNA, SE is made up of three parts, 5 ' end be can with target gene mRNA bonded specific sequence P2, length is between 17nt to 26nt, 3 ' end is to pass through base complementrity bonded specific sequence P3 with supporting probe P1 sequence, and the centre is the spacerarm sequence of 5 oligonucleotide T.Each target gene designs 5 respectively and supports extension probes, to improve the specificity that detects.During use, at every kind of target gene, select to support more than 2 or 2 extension probes can finish detection, specificity and stability all fine (experimental data omission) are preferable over and use 5 to support extension probes, so that specificity reaches best.Every probe after synthetic is mixed with the stock solution of 100pmol/mL respectively with 10mmol/LTris Buffer.The support extension probes (SE) of target gene sees Table 2.

The support extension probes (SE) of table 2 target gene

2) amplification extension probes (AE) is the sequence between linking objective gene mRNA and the signal detection component, AE is made up of three parts, 5 ' end be can with target gene mRNA bonded specific sequence P4,3 ' end be can with the sequence P5 of label probe complementary pairing, (when not using label probe to detect, then 3 ' end also is modified with vitamin H), the centre is the spacerarm sequence of 5 oligonucleotide T.Each target gene designs 10 to 15 amplification extension probes respectively, amplifies thereby detection signal is carried out cascade.Every probe after synthetic is mixed with the stock solution of 100pmol/mL respectively with 10mmol/L Tris Buffer.The amplification extension probes (AE) of target gene sees Table 3.The design of described P5 is according to the common practise of the probe design of this area, it is not for existing inner hairpin structure, do not form dimer between probe interior and probe, do not have mispairing, and all do not have the sequence of non-specific binding between P1, P2, P3, P4 and the total mRNA, it is CCTATGCCTCCCGTGTCTA that the present invention is preferably based composition.During use, at every kind of target gene, the extension probes of selecting to increase more than 5 or 5 can be finished detection, and specificity and stability all fine (experimental data omission) are preferable over and use 10 amplification extension probes, so that specificity reaches best.During use, at every kind of target gene, the extension probes of selecting to increase more than 5 or 5 can be finished detection, and specificity and stability all fine (experimental data omission) are preferable over and use 10 amplification extension probes, so that specificity reaches best.

The amplification extension probes (AE) of table 3 target gene

3) padding sequence (FS) will not seal with the zone of SE, AE specific combination among the target gene mRNA, with the non-specific binding of vitamin H or label probe in the minimizing subsequent reactions, thereby reduce detection background.The Tm value of padding sequence should be approaching with SE, AE, as shown in table 4.

The padding sequence of table 4 target gene (FS)

Three, label probe (LP)

Label probe (LP) is made up of two portions, its 3 ' end be can with the complementary bonded sequence of amplification extension probes sequence P5,5 ' end has biotin labeling, amplifies by combining the cascade that realizes target mRNA signal with the amplification extension probes.

It is as follows to the prescription of the described various solution of detection of clinical sample that the relevant gene mRNA expression of embodiment 2 utilization antimetabolitas curative effects detects liquid-phase chip:

One, lysed sample discharges total RNA

1. FFPE tumor tissue section is scraped from slide glass, put into the 1.5ml centrifuge tube, add 300ul homogenate buffer and 3ul Proteinase K (50ug/ul), mix, 65 ℃ of digestion 2h.

2. the sample of digestion behind the 2h, under the room temperature 13, centrifugal 5 minutes of 000rpm, clear soln is transferred in the new 1.5ml centrifuge tube standby in the middle of drawing.(still do not clarify as solution, then repeat this step 1～2 time.)

Two, target mRNA is fixed on the microballoon by combining with probe specificity

1. take out the probe working fluid and melt,, place on ice at once then 95 ℃ of sex change 5 minutes in room temperature.

2. according to the form below preparation working fluid mixes

3. the above-mentioned working fluid branch for preparing is filled on the hybridization plate 60ul/ hole.Then the above-mentioned sample of handling well is added respectively in the hybridization plate with the 40ul/ hole; Blank adds homogenate buffer 40ul/ hole.Sealing hybridization plate, 54 ℃ ± 1 ℃, 600rpm shakes overnight incubation (16-22h).

4. use washing buffer liquid wetting filter plate 1 minute, remove lavation buffer solution.

5. will hybridize plate and take out, centrifugal 1 minute of 500 * g all is transferred to reaction solution in the filter plate.

6. remove solution, with 200ul lavation buffer solution washing 3 times.

Three, by hybridization target RNA signal is amplified

1. add label probe working fluid 100ul/ hole.50 ℃ ± 1 ℃, the 600rpm concussion was hatched 1 hour.

2. remove solution, with 200ul washings washing 2 times.

Four, combine with SA-PE, and on the liquid-phase chip reading apparatus, detect

1. add SA-PE working fluid 100ul/ hole, 600rpm concussion incubated at room 30min.

2. remove solution,, blot the filter plate bottom with thieving paper with 200ul SA-PE washings washing 2 times.

3. add SA-PE washings 130ul/ hole.Room temperature, the 600rpm concussion was hatched 2 to 5 minutes.

4. reading of data on the liquid-phase chip instrument.

Five, data analysis and cutoff value defines

In 5 target genes, 2 of target genes are respectively: RRM1, TYMS;

3 of housekeeping genes are respectively: B2M, TFRC, TBP;

The fluorescent value that reads is carried out homogenization in accordance with the following methods to be handled:

Step 1: obtain raw data (MFI value)

Step 2: the MFI of sample deducts the MFI=net MFI of blank well N

Step 3: the net MFI value of three housekeeping genes of each sample is got geometrical mean respectively, obtains corresponding G1, G2, G3 ... Gn

Step 4: the net MFI of each sample target gene mRNA obtains corresponding N n divided by the Gn of correspondence.Nn is and gets rid of applied sample amount difference, can carry out relative expression quantity numerical value relatively at sample room.

In the present embodiment 10 routine samples are detected, detected result is as follows:

The relative expression quantity of table 6 10 routine sample raw data (MFI value) and RRM1, TYMS

Embodiment 3: the liquid-phase chip of different interval arm is to the detection of platinum medicine mRNA expression of gene associated level

One, the design (selection of spacerarm) of liquid-phase chip preparation

The support probe that detects liquid-phase chip with ERCC1 is an example, selects different spacerarms respectively for use, and specific design is as shown in table 7.Probe SP, SE and AE synthetic, SP sequence bag is described like embodiment 1 and embodiment 2 by microballoon, detection method.

Table 7 spacerarm and length thereof

The spacerarm kind	Length	Experimental group
			??poly(dT)	??8	??1
??poly(dA)	??8	??2
			??(CH2)n	??15	??3
??poly(TTG)	??3	??4

Two, sample detection

Adopt the liquid-phase chip of above-mentioned design preparation, sample 11-55 detected, detected result following (data are for detecting fluorescent value in the table) by embodiment 2 described testing processes and method:

Table 8 sample detection result (detect fluorescent value＜MFI value 〉)

??Sample	Experimental group 1	Experimental group 2	Experimental group 3	Experimental group 4
					??N	?8	??12	??18	??9
??11	?8596	??8645	??8589	??8649
					??12	?6859	??6845	??6829	??6798
??13	?6591	??6488	??6558	??6524
					??14	?3652	??3695	??3625	??3678
??15	?5625	??5698	??5627	??5675

The detection fluorescent value of 4 groups of designs is carried out statistical analysis, prove that the detection effect of 4 groups of designs does not have difference.Therefore, the design of these 4 kinds of spacerarms is equivalent.

Other is at the liquid-phase chip of supporting extension probes, intervening sequence that the amplification extension probes is inner different, and its result is still reliable and stable, and concrete data are omitted.

Embodiment 4: unlike signal detected components liquid-phase chip is to the detection of platinum medicine mRNA expression of gene associated level

One, the design (signal detection component) of liquid-phase chip preparation

The signal detection component has two kinds of selections, 1) 3 ' end of amplification extension probes 3 ' terminal sequence P5 has biotin labeling; 2) amplification extension probes 3 ' terminal sequence P5 combines by the base complementrity pairing with label probe (LP), and 5 ' of label probe end has biotin labeling simultaneously.These two kinds of signal detection components can realize that all signal amplifies, and detects normal signal.Wherein, the vitamin H activity of applying marking probe is more stable, and effect is more excellent.

Described liquid-phase chip is an example with two kinds of signal detection components that detect the RRM1 gene, and specific design is as shown in table 9.Be consisting of of described liquid-phase chip:

Experimental group 1: support probe link coupled microballoon, support extension probes, padding sequence with embodiment 1, the amplification extension probes has biotin labeling; There is not label probe;

Experimental group 2: support probe link coupled microballoon, support extension probes, padding sequence, label probe with embodiment 1, the amplification extension probes does not have biotin labeling.

Table 9 signal detection component

Two, sample detection

Adopt the liquid-phase chip of above-mentioned design preparation, sample 16-20 detected, detected result following (data are for detecting fluorescent value in the table) by embodiment 2 described testing processes and method:

Table 10 sample detection result (detect fluorescent value＜MFI value 〉)

??Sample	Experimental group 1	Experimental group 2
			??N	??9	??15
??16	??5968	??5989
			??17	??4658	??4689
??18	??8569	??8596
			??19	??3596	??3625
??20	??5681	??5698

The detection fluorescent value of two groups of designs is carried out statistical analysis, prove that the detected result of two groups of designs does not have difference, therefore, these two kinds of signal detection components are equivalent to the detection of signal.Wherein, the signal detection component of applying marking probe, because the activity of its vitamin H is more stable, effect is more excellent.

More than be at the specifying of possible embodiments of the present invention, but this embodiment is not in order to limiting claim of the present invention, does not allly break away from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the claim of the present invention.

Sequence table

＜110〉Guangzhou Yishan Biotechnology Co., Ltd.

＜120〉anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex and detection method

<160>103

<170>PatentIn?version?3.1

<210>1

<211>16

<212>DNA

＜213〉artificial sequence

<400>1

actatacttc?ttcact????????????????????????????16

<210>2

<211>16

<212>DNA

＜213〉artificial sequence

<400>2

tcattcattc?atcaat????????????????????????????16

<210>3

<211>16

<212>DNA

＜213〉artificial sequence

<400>3

ctttctttaa?tctcaa????????????????????????????16

<210>4

<211>16

<212>DNA

＜213〉artificial sequence

<400>4

cattcaaatc?tcaact????????????????????????????????16

<210>5

<211>16

<212>DNA

＜213〉artificial sequence

<400>5

caattacttc?aaatct????????????????????????????????16

<210>6

<211>22

<212>DNA

＜213〉artificial sequence

<400>6

ccgtctgaga?ctcaatgatg?gc?????????????????????????22

<210>7

<211>25

<212>DNA

＜213〉artificial sequence

<400>7

cctcatcttt?gctggtgtac?tccac??????????????????????25

<210>8

<211>24

<212>DNA

＜213〉artificial sequence

<400>8

ttattcaagt?ttcggacaac?gact????????????????????24

<210>9

<211>20

<212>DNA

＜213〉artificial sequence

<400>9

ctgccagacc?ttgtacccca?????????????????????????20

<210>10

<211>21

<212>DNA

＜213〉artificial sequence

<400>10

ctccttggca?aggtcacagc?t???????????????????????21

<210>11

<211>21

<212>DNA

＜213〉artificial sequence

<400>11

ggagaatccc?aggctgtcca?a???????????????????????21

<210>12

<211>22

<212>DNA

＜213〉artificial sequence

<400>12

ttgcagttgg?tcaactccct?gt????????????????????22

<210>13

<211>19

<212>DNA

＜213〉artificial sequence

<400>13

cagagggcat?ggcatggag????????????????????????19

<210>14

<211>21

<212>DNA

＜213〉artificial sequence

<400>14

tagctggcga?tgttgaaagg?c?????????????????????21

<210>15

<211>25

<212>DNA

＜213〉artificial sequence

<400>15

ttcaggtaaa?tatgtgcatc?tccca?????????????????25

<210>16

<211>20

<212>DNA

＜213〉artificial sequence

<400>16

aaggccacgg?agcgagacat???????????????????????20

<210>17

<211>22

<212>DNA

＜213〉artificial sequence

<400>17

ccattctctg?ctggatgacg?tg????????????????????????22

<210>18

<211>24

<212>DNA

＜213〉artificial sequence

<400>18

gctgaaagac?aagtctgaat?gctc??????????????????????24

<210>19

<211>25

<212>DNA

＜213〉artificial sequence

<400>19

ttaactatct?tgggctgtga?caaag?????????????????????25

<210>20

<211>25

<212>DNA

＜213〉artificial sequence

<400>20

ggagacagca?ctcaaagtag?aatta?????????????????????25

<210>21

<211>24

<212>DNA

＜213〉artificial sequence

<400>21

acaatagccc?aagtagccaa?tcat????????????????????????24

<210>22

<211>22

<212>DNA

＜213〉artificial sequence

<400>22

tcggttcctg?ccagtctctc?ac??????????????????????????22

<210>23

<211>24

<212>DNA

＜213〉artificial sequence

<400>23

tctccgacaa?ctttctcttc?aggt????????????????????????24

<210>24

<211>21

<212>DNA

＜213〉artificial sequence

<400>24

ccagcctcac?gagggacata?t???????????????????????????21

<210>25

<211>23

<212>DNA

＜213〉artificial sequence

<400>25

acgccagact?ttgctgagtt?taa????????????23

<210>26

<211>24

<212>DNA

＜213〉artificial sequence

<400>26

cgaagtgcaa?tggtctttag?gtca???????????24

<210>27

<211>23

<212>DNA

＜213〉artificial sequence

<400>27

cgtggttcgt?ggctctctta?tcc????????????23

<210>28

<211>22

<212>DNA

＜213〉artificial sequence

<400>28

tattttcttg?ctgccagtct?gg?????????????22

<210>29

<211>24

<212>DNA

＜213〉artificial sequence

<400>29

catcacagct?ccccaccata?ttct???????????24

<210>30

<211>26

<212>DNA

＜213〉artificial sequence

<400>30

caattctggg?tttgatcatt?ctgtag????????????????26

<210>31

<211>24

<212>DNA

＜213〉artificial sequence

<400>31

gctgctgagc?ttttacaact?ttgc??????????????????24

<210>32

<211>25

<212>DNA

＜213〉artificial sequence

<400>32

gaatctttgt?agagcatata?cgggg?????????????????25

<210>33

<211>21

<212>DNA

＜213〉artificial sequence

<400>33

gttctgctgg?ttgctctttc?g?????????????????????21

<210>34

<211>22

<212>DNA

＜213〉artificial sequence

<400>34

acatacatatt?cagggccag?gg????????????????22

<210>35

<211>24

<212>DNA

＜213〉artificial sequence

<400>35

gtgacttcag?ccaacttctt?aaag??????????????24

<210>36

<211>25

<212>DNA

＜213〉artificial sequence

<400>36

gcctctggta?caggatagta?gttta?????????????25

<210>37

<211>19

<212>DNA

＜213〉artificial sequence

<400>37

gggcgatggc?gtttatttg????????????????????19

<210>38

<211>25

<212>DNA

＜213〉artificial sequence

<400>38

ctctcaaaag?ggtatctcat?cagga????????????????????25

<210>39

<211>25

<212>DNA

＜213〉artificial sequence

<400>39

ctgcttattc?agtaactggg?cttct????????????????????25

<210>40

<211>23

<212>DNA

＜213〉artificial sequence

<400>40

actggagagc?cctcataggt?ttc??????????????????????23

<210>41

<211>21

<212>DNA

＜213〉artificial sequence

<400>41

ggcatcccag?attttcactc?c????????????????????????21

<210>42

<211>21

<212>DNA

＜213〉artificial sequence

<400>42

actggaagcc?ataaactggg?c????????????????????????21

<210>43

<211>23

<212>DNA

＜213〉artificial sequence

<400>43

tccatatctc?tgtattctgc?ccc??????????????????????23

<210>44

<211>23

<212>DNA

＜213〉artificial sequence

<400>44

ggttggtttt?gatggtgtca?atc??????????????????????23

<210>45

<211>22

<212>DNA

＜213〉artificial sequence

<400>45

agatctcttg?gattccaagc?gc???????????????????????22

<210>46

<211>24

<212>DNA

＜213〉artificial sequence

<400>46

aggacagctc?actgttcacc?acat?????????????????????24

<210>47

<211>20

<212>DNA

＜213〉artificial sequence

<400>47

aggcccatgt?ctcccgatct????????????????????????20

<210>48

<211>21

<212>DNA

＜213〉artificial sequence

<400>48

cgcaatcatg?tacgtgagca?g??????????????????????21

<210>49

<211>18

<212>DNA

＜213〉artificial sequence

<400>49

tggcttcagg?cccgtgat??????????????????????????18

<210>50

<211>20

<212>DNA

＜213〉artificial sequence

<400>50

ctgggttctc?gctgaagctg????????????????????????20

<210>51

<211>17

<212>DNA

＜213〉artificial sequence

<400>51

ttcaggaatg?cccgcca????????????????????????17

<21O>52

<211>23

<212>DNA

＜213〉artificial sequence

<400>52

ccaggccaga?aagagagagt?agc?????????????????23

<210>53

<211>23

<212>DNA

＜213〉artificial sequence

<400>53

cctgaatctt?tggagtacgc?tgg?????????????????23

<210>54

<211>24

<212>DNA

＜213〉artificial sequence

<400>54

ggatgaaacc?cagacacata?gcaa????????????????24

<210>55

<211>24

<212>DNA

＜213〉artificial sequence

<400>55

agtgggggtg?aattcagtgt?agta????????????????????24

<210>56

<211>23

<212>DNA

＜213〉artificial sequence

<400>56

tcacacggca?ggcatactca?tct?????????????????????23

<210>57

<211>22

<212>DNA

＜213〉artificial sequence

<400>57

gctgcttaca?tgtctcgatc?cc??????????????????????22

<210>58

<211>20

<212>DNA

＜213〉artificial sequence

<400>58

tgcggcatct?tcaaacctcc?????????????????????????20

<210>59

<211>25

<212>DNA

＜213〉artificial sequence

<400>59

gcaacctgct?cagatacatc?aaaca???????????????????25

<210>60

<211>23

<212>DNA

＜213〉artificial sequence

<400>60

cctctaagtt?gccagccctc?cta????????????????????23

<210>61

<211>25

<212>DNA

＜213〉artificial sequence

<400>61

atagtcccat?agcagatact?tccac??????????????????25

<210>62

<211>25

<212>DNA

＜213〉artificial sequence

<400>62

caatcaagaa?aaagacgatc?acagc??????????????????25

<210>63

<211>23

<212>DNA

＜213〉artificial sequence

<400>63

ctcagttttt?ggttctaccc?ctt????????????????????23

<210>64

<211>21

<212>DNA

＜213〉artificial sequence

<400>64

ctcctggctc?ctccctcact?g????????????????????????21

<210>65

<211>19

<212>DNA

＜213〉artificial sequence

<400>65

cgacgtgctg?cagggaagt???????????????????????????19

<210>66

<211>22

<212>DNA

＜213〉artificial sequence

<400>66

gctggtgaag?tctgtgctgt?cc???????????????????????22

<210>67

<211>22

<212>DNA

＜213〉artificial sequence

<400>67

ttttcattca?gcagcttgat?gg???????????????????????22

<210>68

<211>22

<212>DNA

＜213〉artificial sequence

<400>68

cgagttttga?gcgctgtctt?tg????????????????????????22

<210>69

<211>24

<212>DNA

＜213〉artificial sequence

<400>69

caggattctc?caccaggtaa?acaa??????????????????????24

<210>70

<211>23

<212>DNA

＜213〉artificial sequence

<400>70

gttgcagcct?tactatacgc?cac???????????????????????23

<210>71

<211>19

<212>DNA

＜213〉artificial sequence

<400>71

gcagctgcgg?tacaatccc????????????????????????????19

<210>72

<211>25

<212>DNA

＜213〉artificial sequence

<400>72

tacaaccaag?attcactgtg?gatac????????????????25

<210>73

<211>22

<212>DNA

＜213〉artificial sequence

<400>73

gattatattc?ggcgtttcgg?gc???????????????????22

<210>74

<211>21

<212>DNA

＜213〉artificial sequence

<400>74

atgattaccg?cagcaaaccg?c????????????????????21

<210>75

<211>22

<212>DNA

＜213〉artificial sequence

<400>75

gcacaccatt?ttcccagaac?tg???????????????????22

<210>76

<211>23

<212>DNA

＜213〉artificial sequence

<400>76

ctgttcttca?ctcttggctc?ctg??????????????????23

<210>77

<211>24

<212>DNA

＜213〉artificial sequence

<400>77

acccaacttc?tgtacaactc?tagc????????????????????????24

<210>78

<211>25

<212>DNA

＜213〉artificial sequence

<400>78

tcttgaagtc?caagaactta?gctgg???????????????????????25

<210>79

<211>22

<212>DNA

＜213〉artificial sequence

<400>79

gggtgagcac?aaggccttct?aa??????????????????????????22

<210>80

<211>26

<212>DNA

＜213〉artificial sequence

<400>80

caggaaataa?ctctggctca?taacta??????????????????????26

<210>81

<211>22

<212>DNA

＜213〉artificial sequence

<400>81

tgcacaggtt?gctgcatttg?at????????????????????22

<210>82

<211>19

<212>DNA

＜213〉artificial sequence

<400>82

agccaaatta?caaacagca????????????????????????19

<210>83

<211>19

<212>DNA

＜213〉artificial sequence

<400>83

cgtatgtgtg?ttctgatgt????????????????????????19

<210>84

<211>24

<212>DNA

＜213〉artificial sequence

<400>84

cagagcacca?taataaatag?tttc??????????????????24

<210>85

<211>24

<212>DNA

＜213〉artificial sequence

<400>85

catatcatac?tgaagaattc?cttt????????????????24

<210>86

<211>21

<212>DNA

＜213〉artificial sequence

<400>86

gtcccatagg?tctgtaggag?t???????????????????21

<210>87

<211>18

<212>DNA

＜213〉artificial sequence

<400>87

aagtcccctt?cttctctg???????????????????????18

<210>88

<211>20

<212>DNA

＜213〉artificial sequence

<400>88

atgatgattc?ttctgtcgtc?????????????????????20

<210>89

<211>20

<212>DNA

＜213〉artificial sequence

<400>89

attttcagtg?gctcgatgtg?????????????????????20

<210>90

<211>24

<212>DNA

＜213〉artificial sequence

<400>90

gaagaatcct?gagctttggg?aaag????????????????????24

<210>91

<211>17

<212>DNA

＜213〉artificial sequence

<400>91

cggcccgaat?gctgtca????????????????????????????17

<210>92

<211>22

<212>DNA

＜213〉artificial sequence

<400>92

cagtaagtca?acttcaatgt?cg??????????????????????22

<210>93

<211>23

<212>DNA

＜213〉artificial sequence

<400>93

ctttttcaat?tctctctcca?ttc?????????????????????23

<210>94

<211>20

<212>DNA

＜213〉artificial sequence

<400>94

agagatagaa?agaccagtcc????????????????????????20

<210>95

<211>23

<212>DNA

＜213〉artificial sequence

<400>95

agaatttgga?attcatccaa?tcc????????????????????23

<210>96

<211>23

<212>DNA

＜213〉artificial sequence

<400>96

catatcaata?ttaaaaagca?agc????????????????????23

<210>97

<211>23

<212>DNA

＜213〉artificial sequence

<400>97

ctacattttg?tgcataaagt?gta????????????????????23

<210>98

<211>23

<212>DNA

＜213〉artificial sequence

<400>98

gaagatcatg?tccatgttaa?cat????????????????????23

<210>99

<211>23

<212>DNA

＜213〉artificial sequence

<400>99

cgcaagattt?tcatcttttt?gag????????????????????23

<210>100

<211>23

<212>DNA

＜213〉artificial sequence

<400>100

cacgaaattg?attttcaaca?tac????????????????????23

<210>101

<211>22

<212>DNA

＜213〉artificial sequence

<400>101

ctgaatctta?acaaaatgtt?ga?????????????????????22

<210>102

<211>23

<212>DNA

＜213〉artificial sequence

<400>102

ctaccgttct?tatcaactat?gat????????????????????23

<21O>103

<211>19

<212>DNA

＜213〉artificial sequence

<400>103

tagacacggg?aggcatagg?????????????????????????19

Claims (10)

1. an anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex is characterized in that, mainly comprises:

(1) the support probe link coupled microballoon of modifying with amido, every support probe mainly comprise the spacerarm sequence of 5 ' end and 3 ' end can with the specific sequence P1 that supports the extension probes complementary pairing, described support probe is selected from SEQ.NO.1-SEQ.NO.5, each target gene is selected a kind of microballoon for use, and every kind of microballoon has different fluorescence-encoded;

(2) connect the support extension probes of supporting probe and target gene mRNA, every support extension probes mainly comprise 5 ' end can with corresponding target gene mRNA bonded specific sequence P2, spacerarm sequence, 3 ' end can with the P3 sequence of the specific sequence P1 complementary pairing of corresponding support probe, the specific sequence P2 of described support extension probes includes: at the RRM1 gene be selected among the SEQ.NO.6-SEQ.NO.10 more than 2 or 2 and/or at the TYMS gene be selected among the SEQ.NO.11-SEQ.NO.15 more than 2 or 2; And at the B2M gene be selected among the SEQ.NO.16-SEQ.NO.20 more than 2 or 2, at the TFRC gene be selected among the SEQ.NO.21-SEQ.NO.25 more than 2 or 2 and at the TBP gene be selected among the SEQ.NO.26-SEQ.NO.30 more than 2 or 2;

(3) amplification extension probes, every amplification extension probes include 5 ' end can with target gene mRNA bonded specific sequence P4, spacerarm sequence, 3 ' terminal sequence P5,3 ' end also is modified with vitamin H; The specific sequence P4 of described amplification extension probes includes: at the RRM1 gene be selected among the SEQ.NO.31-SEQ.NO.40 more than 5 or 5 and/or at the TYMS gene be selected among the SEQ.NO.41-SEQ.NO.50 more than 5 or 5; And at the B2M gene be selected among the SEQ.NO.51-SEQ.NO.60 more than 5 or 5, at the TFRC gene be selected among the SEQ.NO.61-SEQ.NO.70 more than 5 or 5 and at the TBP gene be selected among the SEQ.NO.71-SEQ.NO.80 more than 5 or 5; Described P5 is for existing hairpin structure, do not form dimer between probe interior and probe, do not have mispairing, and P1, P2, P3, P4 and total mRNA between all do not have the sequence of non-specific binding.

2. anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex according to claim 1, it is characterized in that, also include padding sequence, include: at the RRM1 gene be selected from one or more among the SEQ.NO.81-SEQ.NO.86, at the TYMS gene be selected from one or more among the SEQ.NO.87-SEQ.NO.90, at one or more among the SEQ.NO.91-SEQ.NO.98 that be selected from of B2M gene, and/or at one or more among the SEQ.NO.99-SEQ.NO.102 that be selected from of TFRC gene.

3. anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex according to claim 1 and 2 is characterized in that, described spacerarm sequence is 5-10 T.

4. anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex according to claim 1 is characterized in that, described P5 consists of CCTATGCCTCCCGTGTCTA.

5. an anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex is characterized in that, mainly includes:

(1) the support probe link coupled microballoon of modifying with amido, every support probe mainly comprise the spacerarm sequence of 5 ' end and 3 ' end can with the specific sequence P1 that supports the extension probes complementary pairing, described support probe is selected from SEQ.NO.1-SEQ.NO.5, each target gene is selected a kind of microballoon for use, and every kind of microballoon has different fluorescence-encoded;

(2) connect the support extension probes of supporting probe and target gene mRNA, every support extension probes mainly comprise 5 ' end can with corresponding target gene mRNA bonded specific sequence P2, spacerarm sequence, 3 ' end can with the P3 sequence of the specific sequence P1 complementary pairing of corresponding support probe, the specific sequence P2 of described support extension probes includes: at the RRM1 gene be selected among the SEQ.NO.6-SEQ.NO.10 more than 2 or 2 and/or at the TYMS gene be selected among the SEQ.NO.11-SEQ.NO.15 more than 2 or 2; And at the B2M gene be selected among the SEQ.NO.16-SEQ.NO.20 more than 2 or 2, at the TFRC gene be selected among the SEQ.NO.21-SEQ.NO.25 more than 2 or 2 and at the TBP gene be selected among the SEQ.NO.26-SEQ.NO.30 more than 2 or 2;

(3) amplification extension probes, every the amplification extension probes include 5 ' end can with target gene mRNA bonded specific sequence P4, spacerarm sequence, 3 ' terminal sequence P5; The specific sequence P4 of described amplification extension probes includes: at the RRM1 gene be selected among the SEQ.NO.31-SEQ.NO.40 more than 5 or 5 and/or at the TYMS gene be selected among the SEQ.NO.41-SEQ.NO.50 more than 5 or 5; And at the B2M gene be selected among the SEQ.NO.51-SEQ.NO.60 more than 5 or 5, at the TFRC gene be selected among the SEQ.NO.61-SEQ.NO.70 more than 5 or 5 and at the TBP gene be selected among the SEQ.NO.71-SEQ.NO.80 more than 5 or 5; Described P5 is for existing hairpin structure, do not form dimer between probe interior and probe, do not have mispairing, and P1, P2, P3, P4 and total mRNA between all do not have the sequence of non-specific binding; With

(4) label probe, described label probe have the sequence with amplification extension probes P5 complementary pairing, and end has biotin modification.

6. anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex according to claim 5, it is characterized in that, also include padding sequence, include: at the RRM1 gene be selected from one or more among the SEQ.NO.81-SEQ.NO.86, at the TYMS gene be selected from one or more among the SEQ.NO.87-SEQ.NO.90, at one or more among the SEQ.NO.91-SEQ.NO.98 that be selected from of B2M gene, and/or at one or more among the SEQ.NO.99-SEQ.NO.102 that be selected from of TFRC gene.

7. according to claim 5 or 6 described anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminexes, it is characterized in that described spacerarm sequence is 5-10 T.

8. anti-metabolism chemotherapeutical medicine curative effect related gene mRNA expressive level detection Luminex according to claim 5 is characterized in that, described P5 consists of CCTATGCCTCCCGTGTCTA.

9. a method that detects anti-metabolism chemotherapeutical medicine curative effect mRNA expression of gene associated level is characterized in that, uses each described liquid-phase chip of claim 1-4, mainly may further comprise the steps:

(1) lysed sample discharges total RNA, gets the cracking mixed solution;

(2) cracking mixed solution, coupling there are microballoon, support extension probes, the amplification extension probes of supporting probe are sealed in the hybridization plate, 54 ℃ ± 1 ℃, 600rpm shakes overnight incubation, support the sequence P3 of extension probes to combine with the P1 that supports probe is complementary, support the specific sequence P2 and the target mRNA specific combination of extension probes, thereby target mRNA is attached on the microballoon; The amplification extension probes has biotin labeling, amplifies thereby the P4 of amplification extension probes and target mRNA specific combination realize the cascade of target mRNA signal;

(3) product and the Streptavidin-phycoerythrin of step (two) react;

(4) detect by fluorescence detector.

10. a method that detects anti-metabolism chemotherapeutical medicine curative effect mRNA expression of gene associated level is characterized in that, uses each described liquid-phase chip of claim 5-8, mainly may further comprise the steps:

(1) lysed sample discharges total RNA, gets the cracking mixed solution;

(2) cracking mixed solution, coupling there are microballoon, support extension probes, the amplification extension probes of supporting probe are sealed in the hybridization plate, 54 ℃ ± 1 ℃, 600rpm shakes overnight incubation, support the sequence P3 of extension probes to combine complementary combination with the P1 that supports probe, support the specific sequence P2 and the target mRNA specific combination of extension probes, thereby target mRNA is attached on the microballoon; The P4 and the target mRNA specific combination of amplification extension probes;

(3) add label probe again, label probe has biotin labeling, and 50 ℃ ± 1 ℃, the 600rpm concussion was hatched 1 hour, and label probe combines with the sequence P5 complementary pairing of amplification extension probes, thereby the cascade that realizes target mRNA signal is amplified;

(4) product and the Streptavidin-phycoerythrin of step (three) react;

(5) detect by fluorescence detector.